Drugs / AGA2115
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06086613 | Oct 2023 → Oct 2024 | osteogenesis imperfecta | Angitia Incorporated Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07557446 | Jun 2026 → Apr 2028 expected | osteogenesis imperfecta | Angitia Biopharmaceuticals Guangzhou Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT07062588 | Dec 2025 → Nov 2027 expected | osteogenesis imperfecta | Angitia Incorporated Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGA2115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07062588 ↗ |
| Route | Subcutaneous | “administered as a subcutaneous (SC) injection” NCT06086613 ↗ |